238 related articles for article (PubMed ID: 16219933)
1. Galectin-1: a link between tumor hypoxia and tumor immune privilege.
Le QT; Shi G; Cao H; Nelson DW; Wang Y; Chen EY; Zhao S; Kong C; Richardson D; O'Byrne KJ; Giaccia AJ; Koong AC
J Clin Oncol; 2005 Dec; 23(35):8932-41. PubMed ID: 16219933
[TBL] [Abstract][Full Text] [Related]
2. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Le QT; Kong C; Lavori PW; O'byrne K; Erler JT; Huang X; Chen Y; Cao H; Tibshirani R; Denko N; Giaccia AJ; Koong AC
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):167-75. PubMed ID: 17707270
[TBL] [Abstract][Full Text] [Related]
3. Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics.
Sørensen BS; Horsman MR; Vorum H; Honoré B; Overgaard J; Alsner J
Radiother Oncol; 2009 Sep; 92(3):443-9. PubMed ID: 19541378
[TBL] [Abstract][Full Text] [Related]
4. Serum protein profile analysis in patients with head and neck squamous cell carcinoma.
Gourin CG; Xia ZS; Han Y; French AM; O'Rourke AK; Terris DJ; Adam BL
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):390-7. PubMed ID: 16618908
[TBL] [Abstract][Full Text] [Related]
5. Heparanase expression at the invasion front of human head and neck cancers and correlation with poor prognosis.
Beckhove P; Helmke BM; Ziouta Y; Bucur M; Dörner W; Mogler C; Dyckhoff G; Herold-Mende C
Clin Cancer Res; 2005 Apr; 11(8):2899-906. PubMed ID: 15837740
[TBL] [Abstract][Full Text] [Related]
6. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation.
Yang MH; Chiang WC; Chou TY; Chang SY; Chen PM; Teng SC; Wu KJ
Clin Cancer Res; 2006 Jan; 12(2):507-15. PubMed ID: 16428493
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 upregulation during tumor progression in head and neck cancer.
Saussez S; Decaestecker C; Mahillon V; Cludts S; Capouillez A; Chevalier D; Vet HK; André S; Toubeau G; Leroy X; Gabius HJ
Laryngoscope; 2008 Sep; 118(9):1583-90. PubMed ID: 18677282
[TBL] [Abstract][Full Text] [Related]
8. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Strauss L; Volland D; Kunkel M; Reichert TE
Med Sci Monit; 2005 Aug; 11(8):BR280-92. PubMed ID: 16049374
[TBL] [Abstract][Full Text] [Related]
9. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma.
Gourin CG; Moretz WH; Weinberger PM; Xia ZS; Liu Z; Terris DJ; Adam BL
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1125-30. PubMed ID: 18025317
[TBL] [Abstract][Full Text] [Related]
10. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
Nelson DW; Cao H; Zhu Y; Sunar-Reeder B; Choi CY; Faix JD; Brown JM; Koong AC; Giaccia AJ; Le QT
Cancer Res; 2005 Jul; 65(14):6151-8. PubMed ID: 16024616
[TBL] [Abstract][Full Text] [Related]
11. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.
Jokilehto T; Rantanen K; Luukkaa M; Heikkinen P; Grenman R; Minn H; Kronqvist P; Jaakkola PM
Clin Cancer Res; 2006 Feb; 12(4):1080-7. PubMed ID: 16489060
[TBL] [Abstract][Full Text] [Related]
12. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model.
Wu CC; Chien KY; Tsang NM; Chang KP; Hao SP; Tsao CH; Chang YS; Yu JS
Proteomics; 2005 Aug; 5(12):3173-82. PubMed ID: 16035111
[TBL] [Abstract][Full Text] [Related]
13. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.
Gross M; Top I; Laux I; Katz J; Curran J; Tindell C; Agus D
Clin Cancer Res; 2007 Apr; 13(7):1979-86. PubMed ID: 17404077
[TBL] [Abstract][Full Text] [Related]
14. Motility-related protein-1/CD9 expression in head and neck squamous cell carcinoma.
Erovic BM; Pammer J; Hollemann D; Woegerbauer M; Geleff S; Fischer MB; Burian M; Frommlet F; Neuchrist C
Head Neck; 2003 Oct; 25(10):848-57. PubMed ID: 12966509
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
Chung JC; Oh MJ; Choi SH; Bae CD
ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
[TBL] [Abstract][Full Text] [Related]
16. Proteomic identification of serum biomarkers for head and neck cancer surveillance.
Gourin CG; Zhi W; Adam BL
Laryngoscope; 2009 Jul; 119(7):1291-302. PubMed ID: 19444892
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma.
Chiang WF; Liu SY; Fang LY; Lin CN; Wu MH; Chen YC; Chen YL; Jin YT
Oral Oncol; 2008 Apr; 44(4):325-34. PubMed ID: 17588803
[TBL] [Abstract][Full Text] [Related]
18. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas.
Saussez S; Camby I; Toubeau G; Kiss R
Head Neck; 2007 Sep; 29(9):874-84. PubMed ID: 17315170
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.
Zhu Y; Denhardt DT; Cao H; Sutphin PD; Koong AC; Giaccia AJ; Le QT
Oncogene; 2005 Sep; 24(43):6555-63. PubMed ID: 16007184
[TBL] [Abstract][Full Text] [Related]
20. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy.
Saussez S; Lorfevre F; Lequeux T; Laurent G; Chantrain G; Vertongen F; Toubeau G; Decaestecker C; Kiss R
Oral Oncol; 2008 Jan; 44(1):86-93. PubMed ID: 17350328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
